Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term ivacaftor in cystic fibrosis patients <24 months with ivacaftor-responsive mutations
2017-001379-21Phase 3Unknown
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Primary safety outcomes and Pharmacodynamic outcomes. Status: unknown.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-001379-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001379-21.